About Teletype
Join
Acumen Research
@acumenresearch
Business
February 19, 2020

Cardiovascular Drugs Market Size Poised to Touch US$ 92.3 Billion by 2026

The global Cardiovascular Drugs market size is anticipated to around USD 92.3 billion by 2026, this market is anticipated to grow with 2.3% CAGR during the forecast time period.

North America dominated the global cardiovascular drugs market in the year 2018. The region has experienced the potential growth owing to the presence of cardiovascular drugs companies such as Novartis AG, Bayer AG, Pfizer Inc., Merck and Co. Inc., and Johnson & Johnson, Eli Lilly and Company among others. The presence of a large customer base and increase in development of cardiovascular drugs is additionally accelerating the regional market growth. Moreover, favorable medicare policies, increase in awareness about health, and growing number of hospitals and clinic centers are expected to enhance the market growth in the global cardiovascular drugs market in future growing prevalence of such diseases further expected to raise the demand for cardiovascular drugsin North America. The Europe region is expected to exhibit a second-largest share in the cardiovascular drugsmarket. Stringent government regulations regarding hospital drugs and rapid industrialization, technological advancement in cardiovascular drugs, growing number of medical pharmaciesin countries, such as Germany, the UK, France, Spain, and Italy, are expected to enhance the market growth in the global cardiovascular drugs market during the forecast.

Asia-Pacific region is expected to exhibit highest CAGR in the cardiovascular drugs market. The rapid growth in the urbanization, growing healthcare industry in developing countries, and liberalization of foreign direct investment in the medical sector are the major driving factor for the region in the global market. Moreover, the rising geriatric population and growing awareness regarding treatment options increases its dominance in the global cardiovascular drugs market in future.

Get Free Download Sample Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1702

Growing demand for cardiovascular drugsin various end user applications, growing awareness about cancer treatment across the globe and multi-functionality of cardiovascular drugs are the main drivers for the market growth of the global cardiovascular drugs market over the forecast period. Furthermore, rising investment in research and development of cardiovascular drugs and supportive government initiatives further grows the demand for cardiovascular drugs over the forecast the period. Moreover, technological advancement and increase in the number of applications, and availability of advanced healthcare facilities in developing countries are expected to enhance the market size. This also expected to open investment opportunities in the global market for the manufacturers in the coming years.

However, stringent government regulations and side effects of drugs are expected to hamper the growth of the global cardiovascular drugs market during the forecast period.

Anti-Coagulants segment have dominated the product segment in the year 2018 and the segment is projected to maintain its dominance over the forecast period from 2019 to 2026. Growing prevalence of blood cancer, epiretinal membrane and diabetic retinopathy and escalating demand for drug treatment further expected to drive the demand for the segment. The manufacturers Takeda Pharmaceutical Company Ltd, Otsuka Holdings Co., Ltd, and Novartis AG, are the mainly investing in the development ofanti-coagulants vectors, which expected the lead the market in the coming years.

Related Reports

Hospital pharmacies segment dominated the cardiovascular drugs market on the basis of distribution channelin the year 2018. The major factors that are driving the growth of this segment are availability of pharmacies in hospitals and growing number of hospitals across the globe. This expected to enhance the dominance of the hospital segment in the global market over the forecast period.

Some of the leading competitors are Otsuka Holdings Co., Ltd., Gilead Sciences Inc., Sun Pharma Industries, Abbott Laboratories, Novartis AG, Bayer AG, Pfizer Inc., Merck and Co. Inc., and Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Ltd.

Some of the key observations regarding cardiovascular drugs industry include:

  • In July 2019, Abbott Medical Optics Inc. announced partnership agreement with Johnson & Johnson, a provider of advanced software solutions for life science R&D. The partnership increases the development of cardiovascular drugsproducts and increases the efficiency of strain development processes.
  • In February 2019, Novartis AG signed partnership agreement with Blackstones life science. The partnership focuses on development of cardiovascular drugs and other medical products.
  • In November 2018, Novartis AG received approval from European commission for luxturna, a gene therapy to treat patients with a vision loss. The approval enhances the brand identity of the company and enhances its customer base.
  • In January 2017, Novartis AG signed partnership agreement with Caribou. The partnership focuses on innovation and development of drugs and therapy treatment.
  • In August 2017, Takeda Pharmaceutical Company Ltd signed partnership agreement with Cardurion Pharmaceuticals. The partnership focuses on development of cardiovascular drugs and next generation medical products.

Market By Drug Type

  • Anti-Hyperlipidemics
  • Anti-Hypertensive
  • Anti-Coagulants
  • Anti-Arrhythmic
  • Anti-Fibrinolytic
  • Others

Market By Disease Indication

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Others

Market By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market By Geography

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1702

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Cardiovascular Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cardiovascular Drugs Market By Drug Type
1.2.2.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison By Drug Type (2015-2026)
1.2.2.2. Global Cardiovascular Drugs Market Revenue Share By Drug Type in 2018
1.2.2.3. Anti-Hyperlipidemics
1.2.2.4. Anti-Hypertensive
1.2.2.5. Anti-Coagulants
1.2.2.6. Anti-Arrhythmic
1.2.2.7. Anti-Fibrinolytic
1.2.2.8. Others
1.2.3. Cardiovascular Drugs Market By Disease Indication
1.2.3.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison By Disease Indication (2015-2026)
1.2.3.2. Global Cardiovascular Drugs Market Revenue Share By Disease Indication in 2018
1.2.3.3. Hypertension
1.2.3.4. Hyperlipidemia
1.2.3.5. Coronary Artery Disease
1.2.3.6. Others
1.2.4. Cardiovascular Drugs Market By End-Use
1.2.4.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison By End-Use (2015-2026)
1.2.4.2. Global Cardiovascular Drugs Market Revenue Share By End-Use in 2018
1.2.4.3. Hospitals Pharmacies
1.2.4.4. Retail Pharmacies
1.2.4.5. Online Pharmacies
1.2.4.6. Others
1.2.5. Cardiovascular Drugs Market By Geography
1.2.5.1. Global Cardiovascular Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Cardiovascular Drugs Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cardiovascular Drugs Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Cardiovascular Drugs Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Cardiovascular Drugs Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Cardiovascular Drugs Major Manufacturers in 2018

CHAPTER 4. CARDIOVASCULAR DRUGS MARKET By DRUG TYPE
4.1. Global Cardiovascular Drugs Revenue By Drug Type
4.2. Anti-Hyperlipidemics
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Anti-Hypertensive
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Anti-Coagulants
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Anti-Arrhythmic
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Anti-Fibrinolytic
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Others
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. CARDIOVASCULAR DRUGS MARKET BY DISEASE INDICATION
5.1. Global Cardiovascular Drugs Revenue By Disease Indication
5.2. Hypertension
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hyperlipidemia
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Coronary Artery Disease
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. CARDIOVASCULAR DRUGS MARKET BY END-USE
6.1. Global Cardiovascular Drugs Revenue By End-Use
6.2. Hospitals Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Retail Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Online Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA CARDIOVASCULAR DRUGS MARKET BY COUNTRY
7.1. North America Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Cardiovascular Drugs Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE CARDIOVASCULAR DRUGS MARKET BY COUNTRY
8.1. Europe Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET BY COUNTRY
9.1. Asia-Pacific Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA CARDIOVASCULAR DRUGS MARKET BY COUNTRY
10.1. Latin America Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET BY COUNTRY
11.1. Middle East & Africa Cardiovascular Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East & Africa Cardiovascular Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.5. Rest of Middle East & Africa
11.5.1. Market Revenue and Forecast By Drug Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Disease Indication, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE
12.1. Novartis AG
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Bayer AG
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Pfizer Inc.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Merck and Co. Inc.
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Johnson & Johnson
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Eli Lilly and Company
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Takeda Pharmaceutical Company Ltd
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Otsuka Holdings Co., Ltd
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Gilead Sciences Inc.
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Sun Pharma Industries
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Abbott Laboratories
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Product Portfolio
12.11.5. Key Developments
12.11.6. Strategies
12.12. Others
12.12.1. Company Snapshot
12.12.2. Overview
12.12.3. Financial Overview
12.12.4. Product Portfolio
12.12.5. Key Developments
12.12.6. Strategies

CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/1702

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1-407-915-4157 OR +1-408-900-9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us: Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218, Rowland Heights, CA 91748 United States
Tel: +1-407-915-4157 OR +1-408-900-9135
Email: sales@acumenresearchandconsulting.com Website: https://www.acumenresearchandconsulting.com

Acumen Research
February 19, 2020, 11:25
0 views
0 reactions
0 replies
0 reposts